A novel approach to identifying antiarrhythmic drug targets

Drug Discovery Today

Volumn 8, Issue 4, 2003, Pages 162-167

  Gilmour Jr , Robert F ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRETYLIUM; CALCIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL BLOCKING AGENT; VERAPAMIL;

ANTIARRHYTHMIC ACTIVITY; CAUSE OF DEATH; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; HEART ARRHYTHMIA; HEART DEATH; HEART MUSCLE POTENTIAL; HEART RHYTHM; HEART VENTRICLE FIBRILLATION; HUMAN; REVIEW;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM CHANNEL BLOCKERS; DRUG DESIGN; HUMANS; POTASSIUM CHANNELS; VENTRICULAR FIBRILLATION;

EID: 0037441474     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02567-9     Document Type: Review

References (58)

1. Zipes D.P., Wellens H.J. Sudden cardiac death. Circulation. 98:1998;2334-2351.
2. Myerburg R.J., et al. Life-threatening ventricular arrythmias: the link between epidemiology and pathophysiology. Zipes D.P., Jalife J. Cardiac Electrophysiology: From Cell to Bedside. 1995;723-731 WB Saunders Co, Philadelphia.
3. Krinsky V.I., Efimov I.R. Votices with linear cores in mathematical models of excitable media. Physica A. 188:1992;55-60.
4. Winfree A.T. Evolving perspectives during 12 years of electrical turbulence. Chaos. 8:1998;1-20.
5. Allessie M.A., et al. Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The 'leading circle' concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ. Res. 41:1977;9-18.
6. Frazier D.W., et al. Stimulus-induced critical point. Mechanism for electrical initiation of reentry in normal canine myocardium. J. Clin. Invest. 83:1989;1039-1052.
7. Witkowski F.X., et al. Spatiotemporal evolution of ventricular fibrillation. Nature. 392:1998;78-82.
8. Weiss J.N., et al. Chaos and the transition to ventricular fibrillation: a new approach to antiarrhythmic drug evaluation. Circulation. 99:1999;2819-2826.
9. Chen P.S., et al. Mechanism of ventricular vulnerability to single premature stimuli in open-chest dogs. Circ. Res. 62:1988;1191-1209.
10. Gilmour R.F. Jr, Chialvo D.R. Electrical restitution, critical mass, and the riddle of fibrillation. J. Cardiovasc. Electrophysiol. 10:1999;1087-1089.
11. Pertsov A.M., et al. Spiral waves of excitation underlie reentrant activity in isolated cardiac muscle. Circ. Res. 72:1993;631-650.
12. Garfinkel A., et al. Preventing ventricular fibrillation by flattening cardiac restitution. Proc. Natl. Acad. Sci. U. S. A. 97:2000;6061-6066.
13. Riccio M.L., et al. Electrical restitution and spatiotemporal organization during ventricular fibrillation. Circ. Res. 84:1999;955-963.
14. Panfilov A., Pertsov A. Ventricular fibrillation: evolution of the multiple wave hypothesis. Philos. Trans. R. Soc. Lond. Ser. A. 359:2001;1315-1325.
15. Fenton F.H., et al. Multiple mechanisms of spiral wave breakup in a model of cardiac electrical activity. Chaos. 12:2002;852-892.
16. Karma A. Spiral breakup in model equations of action potential propagation in cardiac tissue. Phys. Rev. Lett. 71:1993;1103-1106.
17. Karma A. Electrical alternans and spiral wave breakup in cardiac tissue. Chaos. 4:1994;461-472.
18. Moe G.K. A computer model of atrial fibrillation. Am. Heart J. 67:1964;200-220.
19. Guevara M.R., et al. Electrical alternans and period doubling bifurcations. IEEE Comp. Cardiol. 562:1984;167-170.
20. Chialvo D.R., et al. Low dimensional chaos in cardiac tissue. Nature. 343:1990;653-657.
21. Karagueuzian H.S., et al. Action potential alternans and irregular dynamics in quinidine-intoxicated ventricular muscle cells. Implications for ventricular proarrhythmia. Circulation. 87:1993;1661-1672.
22. Nolasco J.B., Dahlen R.W. A graphic method for the study of alternation in cardiac action potentials. J. Appl. Physiol. 25:1968;191-196.
23. Rosenbaum D.S., et al. Electrical alternans and vulnerability to ventricular arrhythmias. New Engl. J. Med. 330:1994;235-241.
24. Pastore J.M., et al. Mechanism linking T-wave alternans to the genesis of cardiac fibrillation. Circ. Res. 99:1999;1385-1394.
25. Koller M.L., et al. Dynamic restitution of action potential duration during electrical alternans and ventricular fibrillation. Am. J. Physiol. 275:1998;H1635-H1642.
26. o on electrical restitution and activation dynamics during ventricular fibrillation. Am. J. Physiol. Heart Circ. Physiol. 279:2000;H2665-H2672.
27. Fox J.J., et al. Spatiotemporal transition to conduction block in canine ventricle. Circ. Res. 90:2002;289-296.
28. Chen P.S., et al. Spirals, chaos, and new mechanisms of wave propagation. Pacing Clin. Electrophysiol. (PACE). 20:1997;414-421.
29. Panfilov A. Spiral breakup as a model of ventricular fibrillation. Chaos. 8:1998;57-64.
30. 2+ dynamics and the stability of ventricular tachycardia. Biophys. J. 77:1999;2930-2941.
31. Winslow R.L., et al. Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, II. Circ. Res. 84:1999;571-586.
32. Luo C.H., Rudy Y. A dynamic model of the cardiac ventricular action potential, I: simulation of ionic currents and concentration changes. Circ. Res. 74:1994;1071-1096.
33. Fox J.J., et al. Ionic mechanism of cardiac alternans. Am. J. Physiol. 282:2002;H516-H530.
34. + channel activity is regulated by changes in phosphatidyl inositol 4,5-bisphosphate. Circ. Res. 89:2001;1168-1176.
35. Kiehn J. Regulation of the cardiac repolarizing HERG potassium channel by protein kinase A. Trends Cardiovasc. Med. 10:2001;205-209.
36. Kr, through a reduction in C-type inactivation in guinea pig ventricular myocytes. J. Physiol. 522:2000;391-402.
37. Marx S.O., et al. Requirement of a macromolecular signaling complex for β adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science. 295:2002;496-499.
38. Reuter H., Scholz H. The regulation of calcium conductance of cardiac muscle by adrenaline. J. Physiol. 246:1977;49-62.
39. + current. Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol. 96:1990;195-215.
40. Rocchetti M., et al. Rate dependency of delayed rectifier currents during the guinea pig ventricular action potential. J. Physiol. 534:2001;721-732.
41. Gintant G.A. Characterization and functional consequences of delayed rectifier current transient in ventricular repolarization. Am. J. Physiol. 278:2000;H806-H817.
42. Ks in electrical heterogeneity. Am. J. Physiol. 268:1995;H604-H613.
43. Clay J.R., et al. A quantitative description of the E-4031-sensitive repolarization current in rabbit ventricular myocytes. Biophys. J. 69:1995;1830-1837.
44. Nuss H.B., et al. Overexpression of a human potassium channel suppresses cardiac hyperexcitability in rabbit ventricular myocytes. J. Clin. Invest. 103:1999;889-896.
45. Waldo A.L., et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with ORal D-sotalol. Lancet. 348:1996;7-12.
46. Hondeghem L.M., Snyders D.J. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation. 81:1990;686-690.
47. + channel by the gastrointestinal prokinetic agent cisapride. Am. J. Physiol. 273:1997;H2534-H2538.
48. Roy M., et al. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation. 94:1996;817-823.
49. Mitcheson J.S., et al. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U. S. A. 97:2000;12329-12333.
50. Mitcheson J.S., et al. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U. S. A. 97:2000;12329-12333.
51. Keating M.T., Sanguinetti M.C. Molecular genetic insights into cardiovascular disease. Science. 272:1996;681-685.
52. Curran M.E., et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 80:1995;795-803.
53. Roden D.M., Balser J.R. A plethora of mechanisms in the HERG-related long QT syndrome. Genetics meets electrophysiology. Cardiovasc. Res. 44:1999;242-246.
54. Kr potassium channel. Cell. 81:1995;299-307.
55. Hund T.J., et al. Dynamics of action potential head-tail interaction during reentry in cardiac tissue: ionic mechanisms. Am. J. Physiol. 279:2000;H1869-H1879.
56. Echt D.S., et al. Mortality and morbidity in patients receiving encainide, flecainide or placebo: the cardiac arrhythmia suppression trial. New Engl. J. Med. 324:1991;781-788.
57. Yusuf S., et al. Overview of results of randomized clinical trials in heart disease: I. Treatments following myocardial infarction. J. Am. Med. Assoc. 260:1988;2088-2095.
58. Held P.H., Yusuf S. Impact of calcium channel blockers on mortality. Singh B.N., et al. Cardiovascular Pharmacology and Therapeutics. 1994;525-533 Churchill Livingston.